Based on this YouTube video's total view count of 7.55K views and industry-standard rates, the estimated total earning is $5 - $15 through ad revenue. Historical data is not yet available to calculate daily, weekly, or monthly averages.

Explore How AI Drug Discovery is Supercharging Pace of Innovation with Tom Miller Co-Founder & CEO of Iambic with 7,550 views, 664 likes, and 14 comments. Experience the impact of this video content that has captured audience attention.

Explore the future of drug development with AI that could compress decades of research into just years! Joining us at Catalio Conversations is Tom Miller, co-founder of Iambic, where he reveals how combining cutting-edge neural models with high-throughput experimentation is rewriting the rules of pharmaceutical innovation – think a cancer drug designed, optimized, and FDA-approved in under two years! Tom's journey from Caltech professor to drug discovery entrepreneur – alongside co-founder Fred Manby – offers a masterclass in turning academic breakthroughs into real-world medicines. From Iambic's game-changing Neuroplexer model that predicts exactly how drugs bind to proteins, to their landmark cancer candidate IM1363, this episode pulls back the curtain on what genuinely AI-powered drug discovery looks like. And with strategic partnerships with Lundbeck, Revolution Medicines, and Takeda already in place, Iambic isn't just promising the future – they're building it. Perfect for life sciences leaders, AI enthusiasts, and anyone curious about the next frontier of medicine, this episode reveals the paradigm shifts redefining what's possible in pharma. Don't miss this front-row seat to the biggest leap in pharmaceutical history – the next blockbuster cancer drug might already be designed by an algorithm, waiting to save your life. Timestamped Summary: 00:00 - Introduction to Catalio Conversations and guest Tom Miller 00:29 - Tom’s journey from Caltech professor to drug innovator 01:28 - Collaboration with co-founder Fred Manby 01:55 - Balancing scientific integrity with entrepreneurial agility 02:21 - Lessons from early Iambic experiments 03:13 - AI prediction and high-throughput experimentation 03:43 - Defining drug targets and designing molecules 04:11 - Neuroplexer in predicting drug-protein binding 05:06 - Multi-property optimization in discovery 06:24 - Rapid development of cancer candidate IM1363 06:49 - AI reducing drug development timelines 07:16 - Industry impact of AI-designed medicines 07:59 - Partnerships with Lundbeck and Revolution Medicines 08:55 - Building credibility through collaborations 09:21 - Genuine AI transformation vs. superficial branding 09:45 - Scaling advantage of AI-powered discovery 10:36 - AI’s potential in biological complexity 11:31 - Future of AI in drug development 12:24 - Iambic’s identity: AI platform or drug company? 13:21 - Future goals for Iambic and industry impact 14:13 - Promising targets like transcription factors 14:42 - Closing remarks and encouragement for innovation About Catalio Conversations: Welcome to Catalio Conversations! We spotlight founders & CEOs across innovative healthcare, AI & life sciences, who are building the next generation of disruptors in the space – from drug discovery and autonomous labs to clinical intelligence & beyond. The future starts here. Resources & Links: Iambic Latest News - https://www.youtube.com/watch?v=fe0i_oE3qkI Iambic Official Website - https://www.iambic.ai/ Compliance disclaimer: Martha Petrocheilos is employed at Catalio Capital Management, LP. All views expressed here by Catalio employees and guests are solely their opinions and do not reflect the opinions of Catalio Capital Management, LP. You should not treat any opinions expressed as specific endorsement to make a particular investment. Any past performance discussed is not indicative of future results and investment in a fund entails a high degree of risk, including the risk of loss. References to any securities are for informational purposes only, and do not constitute an investment recommendation or offer to provide investment advisory services.

With SocialCounts.org’s view counter, track your YouTube video’s live view count and YouTube likes count in real time with fast, reliable updates.

Watch every YouTube video live view count rise with our real-time YouTube views tracker—built for accuracy and minimal delay.

Follow YouTube real time views as they happen, using our dedicated view counter for YouTube videos.

Get up-to-date live view count on YouTube and see real-time growth with SocialCounts.org’s smart tracking tools.